Transcatheter XXXX for @entity472 .

@entity1 @entity64 @entity886 @entity583 @entity472
BACKGROUND: Short-term results are presented from our first year of experience with transcatheter @entity886 [corrected] (TAVI) at the University Hospital of North Norway. MATERIALS AND METHODS: TAVI was used to treat 25 @entity1 with @entity472 [corrected] from September 2008 to August 2009. 25 @entity1 operated with conventional aortic valve replacement (AVR) served as controls. RESULTS: The TAVI group had a significantly higher EuroSCORE (p < 0.001) than the AVR group. No @entity1 in the TAVI group were treated in the intensive care unit while those in the AVR group received 38 days of intensive care in total. The TAVI group had shorter operating times (p < 0.001), larger mean valve sizes (p < 0.001) and significantly fewer postoperative transfusions (p < 0.001) than the ACR group. Peri-operative @entity64 and @entity583 did not occur in the TAVI group while there was one incidence of @entity64 and one @entity583 in the AVR group. The postoperative transvalvular mean gradient decreased in both groups (p < 0.001) and was significantly lower in the TAVI group (p = 0.001). The NYHA class improved significantly in the TAVI group (p < 0.001). No @entity1 needed implantation of a permanent pacemaker. 30-day mortality was four @entity1 in the AVR group and one @entity1 in the TAVI group. After discharge one @entity1 died in each group. INTERPRETATION: TAVI is safe and effective for selected @entity1 with @entity472 [corrected] who are assessed as high risk for AVR. Long-term results are needed and will be decisive for use of this approach in the future.
